Emilie Vangsgaard Rosager1, Christian Møller1, Magnus Sjögren2. 1. Mental Health Center Ballerup, Copenhagen University, Institute for Clinical Medicine, Maglevaenget 32, 2750, Ballerup, Denmark. 2. Mental Health Center Ballerup, Copenhagen University, Institute for Clinical Medicine, Maglevaenget 32, 2750, Ballerup, Denmark. jan.magnus.sjoegren@regionh.dk.
Abstract
INTRODUCTION: Anorexia nervosa (AN) is a psychiatric disorder with a high mortality and unknown etiology, and effective treatment is lacking. For decades, cannabis has been known to cause physical effects on the human body, including increasing appetite, which may be beneficial in the treatment of AN. OBJECTIVE: To systematically review the literature for evidence of an effect of cannabinoids on (1) weight gain, and (2) other outcomes, in AN. METHOD: A systematic review was done using three databases Embase, PubMed and Psychinfo. The review was registered in PROSPERO with ID number CRD42019141293 and was done according to PRISMA guidelines. RESULTS: There were 1288 studies identified and after thorough review and exclusion of copies, 4 studies met the inclusion criteria. Three studies used the same AN population and utilized data from one original study, leaving only two original studies. Both of these were Randomized Controlled Trials that explored the effects of delta-9-tetrahydrocannabinol (Δ9-THC) or dronabinol in AN, whereof one study was properly designed and powered and showed a weight increase of an added 1 kg over 4 weeks over placebo. DISCUSSION AND CONCLUSION: There are few studies and the level of evidence is low. The only properly designed, low bias and highly powered study found a weight increasing effect of dronabinol in AN, while the other, using Δ9-THC at a high dose, found no effect and where the dose may have counteracted the weight gaining effects due to adverse events. More research on cannabinoids in anorexia nervosa is warranted, especially its effects on psychopathology. LEVEL OF EVIDENCE: Level I, systematic review.
INTRODUCTION:Anorexia nervosa (AN) is a psychiatric disorder with a high mortality and unknown etiology, and effective treatment is lacking. For decades, cannabis has been known to cause physical effects on the human body, including increasing appetite, which may be beneficial in the treatment of AN. OBJECTIVE: To systematically review the literature for evidence of an effect of cannabinoids on (1) weight gain, and (2) other outcomes, in AN. METHOD: A systematic review was done using three databases Embase, PubMed and Psychinfo. The review was registered in PROSPERO with ID number CRD42019141293 and was done according to PRISMA guidelines. RESULTS: There were 1288 studies identified and after thorough review and exclusion of copies, 4 studies met the inclusion criteria. Three studies used the same AN population and utilized data from one original study, leaving only two original studies. Both of these were Randomized Controlled Trials that explored the effects of delta-9-tetrahydrocannabinol (Δ9-THC) or dronabinol in AN, whereof one study was properly designed and powered and showed a weight increase of an added 1 kg over 4 weeks over placebo. DISCUSSION AND CONCLUSION: There are few studies and the level of evidence is low. The only properly designed, low bias and highly powered study found a weight increasing effect of dronabinol in AN, while the other, using Δ9-THC at a high dose, found no effect and where the dose may have counteracted the weight gaining effects due to adverse events. More research on cannabinoids in anorexia nervosa is warranted, especially its effects on psychopathology. LEVEL OF EVIDENCE: Level I, systematic review.
Entities:
Keywords:
Anorexia nervosa; Cannabinoids; Dronabinol; Medical cannabis; Placebo; Systematic review
Authors: A C Howlett; F Barth; T I Bonner; G Cabral; P Casellas; W A Devane; C C Felder; M Herkenham; K Mackie; B R Martin; R Mechoulam; R G Pertwee Journal: Pharmacol Rev Date: 2002-06 Impact factor: 25.468
Authors: H Gross; M H Ebert; V B Faden; S C Goldberg; W H Kaye; E D Caine; R Hawks; N Zinberg Journal: J Clin Psychopharmacol Date: 1983-06 Impact factor: 3.153
Authors: Joshua Aviram; Gil M Lewitus; Yelena Vysotski; Mahmoud Abu Amna; Anton Ouryvaev; Shiri Procaccia; Idan Cohen; Anca Leibovici; Luiza Akria; Dimitry Goncharov; Neomi Mativ; Avia Kauffman; Ayelet Shai; Gil Bar-Sela; David Meiri Journal: Front Pain Res (Lausanne) Date: 2022-05-20